Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Malignant Solid Neoplasm and descendants · 95% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01309490 | Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | Phase 1 / Phase 2 | terminated | Mar 7, 2011 | Jewish General Hospital | Low accrual, competing studies | Enrollment / accrual |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With… | Phase 1 | terminated | Oct 8, 2024 | Exelixis | Company Decision | Sponsor / business decision |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT04820894 | Perception of Cure Among Patients With Metastatic Cancer | — | withdrawn | Mar 29, 2021 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT04171219 | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers | Phase 2 | terminated | Nov 20, 2019 | M.D. Anderson Cancer Center | There is no PR/CR observed in the first stage, so study stopped without proceeding to the stage 2… | Efficacy / futility |
| NCT05600556 | Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment… | N/A | withdrawn | Oct 31, 2022 | Thomas Jefferson University | ViewRay (funding sponsor) bankruptcy | Funding |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | Phase 4 | withdrawn | Feb 19, 2025 | Mayo Clinic | low/slow accrual | Enrollment / accrual |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05135650 | Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic… | Phase 1 | terminated | Nov 26, 2021 | Fred Hutchinson Cancer Center | Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab | Other (stated, no rule matched) |
| NCT04370834 | Tocilizumab for Patients With Cancer and COVID-19 Disease | Phase 2 | terminated | May 1, 2020 | National Cancer Institute (NCI) | Other - Randomized data no longer support continuation | Other (stated, no rule matched) |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory… | Phase 1 | terminated | Oct 28, 2021 | Molecular Partners AG | After completion of the dose-escalation part of the study, the safety profile of MP0317 in… | Safety / toxicity |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or… | Phase 1 | terminated | Feb 2, 2016 | Mayo Clinic | lack of funding | Funding |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or… | Phase 1 | withdrawn | Dec 16, 2022 | Mayo Clinic | Sponsor business considerations | Sponsor / business decision |
| NCT04060849 | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell… | Phase 1 | terminated | Aug 19, 2019 | Fred Hutchinson Cancer Center | The study was closed to accrual according to the Fred Hutch/University of Washington/Seattle… | Enrollment / accrual |
| NCT05056831 | Multicomponent Physical Activity Intervention for the Reduction of Psychosocial Distress… | N/A | terminated | Sep 27, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or… | Phase 1 | terminated | Mar 27, 2014 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT01296555 | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in… | Phase 1 | terminated | Feb 15, 2011 | Genentech, Inc. | The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical… | Drug supply |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft… | Early Phase 1 | withdrawn | Aug 25, 2022 | City of Hope Medical Center | Funding | Funding |
| NCT03887702 | Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus… | Phase 3 | terminated | Mar 25, 2019 | SWOG Cancer Research Network | inability to accrue | Enrollment / accrual |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced… | Phase 3 | withdrawn | Jun 3, 2022 | Mayo Clinic | Closed due to slow accrual | Enrollment / accrual |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in… | Phase 2 | withdrawn | May 6, 2024 | National Cancer Institute (NCI) | No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior… | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer… | Phase 2 | terminated | Jul 10, 2020 | OHSU Knight Cancer Institute | Insufficient accrual rate | Enrollment / accrual |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT04168320 | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment(SBRT-PATHY) | Phase 1 | terminated | Nov 19, 2019 | Klinikum Klagenfurt am Wörthersee | Because of the prolonged/poor patient recruitment | Enrollment / accrual |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and… | Phase 1 / Phase 2 | terminated | Dec 8, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving… | Early Phase 1 | withdrawn | Feb 15, 2023 | City of Hope Medical Center | withdrawn per PI | Other (stated, no rule matched) |
| NCT04729725 | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors,… | Phase 1 | terminated | Jan 28, 2021 | M.D. Anderson Cancer Center | The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity. | Safety / toxicity |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT04081298 | eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino…(MiVSEEV) | N/A | terminated | Sep 9, 2019 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03884517 | Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | Phase 1 | terminated | Mar 21, 2019 | Bio-Thera Solutions | Considering that the safety risk will affect the subsequent development, it is decided to terminate… | Safety / toxicity |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | Phase 1 / Phase 2 | terminated | Apr 23, 2009 | Bristol-Myers Squibb | not stated | Not stated |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors… | — | withdrawn | Dec 23, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05038384 | Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work | — | withdrawn | Sep 9, 2021 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT04800627 | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally… | Phase 1 / Phase 2 | terminated | Mar 16, 2021 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive… | Phase 1 | withdrawn | Jul 25, 2022 | Pamela Munster | Sponsor funding | Funding |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT05010096 | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With… | Phase 1 | withdrawn | Aug 18, 2021 | M.D. Anderson Cancer Center | No participants Enrolled | Enrollment / accrual |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | Phase 1 | terminated | Jun 15, 2016 | EpicentRx, Inc. | Sufficient patients enrolled to end study | Enrollment / accrual |
| NCT04803630 | Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study | Early Phase 1 | withdrawn | Mar 18, 2021 | Roswell Park Cancer Institute | Awaiting grant funding for next phase of study | Funding |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | Phase 1 | terminated | Aug 18, 2017 | Polaris Group | Changing Corporate Priorities | Other (stated, no rule matched) |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced… | Phase 2 | withdrawn | Mar 11, 2019 | Sameek Roychowdhury | PI decision | Other (stated, no rule matched) |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and… | Phase 2 | withdrawn | Jul 2, 2020 | OHSU Knight Cancer Institute | limited resources | Other (stated, no rule matched) |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | Oncovir, Inc. | Recruiting target patients is intermittent making it impracticable to enroll the required study… | Enrollment / accrual |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes… | Phase 2 | withdrawn | Jun 19, 2020 | National Cancer Institute (NCI) | zero accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 29, 2025source: clinicaltrials